Patient characteristics
| No. of patients . | 841 . |
|---|---|
| Median age at diagnosis, y (range) | 57.2 (30-91) |
| Sex | |
| Male | 503 (60%) |
| Female | 338 (40%) |
| Rai stage | |
| 0-1 | 657 (78%) |
| 2 | 126 (15%) |
| 3-4 | 58 (7%) |
| Median time from diagnosis to Sc, y | 3 |
| Median TFS, y | 4 |
| No. of treated patients | 533 (63%) |
| No. of patients with IGHV status | 830 (98%) |
| IGHVUM | 376 (45%) |
| IGHVMU | 454 (55%) |
| No. of patients with ZAP-70 expression | 838 (99%) |
| ZAP-70 positive | 307 (37%) |
| ZAP-70 negative | 531 (63%) |
| No. of patients with fluorescence in situ hybridization data | 656 (78%) |
| Del(17p) | 64 (10%) |
| Del(11q) | 78 (12%) |
| Trisomy 12 | 103 (16%) |
| Del(13q) | 263 (40%) |
| Normal karyotype | 146 (22%) |
| No. of patients . | 841 . |
|---|---|
| Median age at diagnosis, y (range) | 57.2 (30-91) |
| Sex | |
| Male | 503 (60%) |
| Female | 338 (40%) |
| Rai stage | |
| 0-1 | 657 (78%) |
| 2 | 126 (15%) |
| 3-4 | 58 (7%) |
| Median time from diagnosis to Sc, y | 3 |
| Median TFS, y | 4 |
| No. of treated patients | 533 (63%) |
| No. of patients with IGHV status | 830 (98%) |
| IGHVUM | 376 (45%) |
| IGHVMU | 454 (55%) |
| No. of patients with ZAP-70 expression | 838 (99%) |
| ZAP-70 positive | 307 (37%) |
| ZAP-70 negative | 531 (63%) |
| No. of patients with fluorescence in situ hybridization data | 656 (78%) |
| Del(17p) | 64 (10%) |
| Del(11q) | 78 (12%) |
| Trisomy 12 | 103 (16%) |
| Del(13q) | 263 (40%) |
| Normal karyotype | 146 (22%) |
Sc, sample collection.